The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …

Background In metastatic breast cancer, hormone and/or human epidermal growth factor
receptor 2 (HER2)–targeted therapy decision-making is still largely based on tissue …

Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies,
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …

Metastasis resistant to therapy is the major cause of death from cancer. Despite almost 200
years of study, the process of tumor metastasis remains controversial. Stephen Paget initially …

Intratumor heterogeneity represents a major obstacle to effective cancer treatment and
personalized medicine. However, investigators are now elucidating intratumor heterogeneity …

Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor
characteristics in breast cancer to guide therapy. Anti-HER2 treatment has clear survival …

A long-term goal of cancer diagnosis is to develop tumor-imaging techniques that have
sufficient specificity and sensitivity. To achieve this goal, minimizing the background signal …

Purpose We evaluated whether patients with human epidermal growth factor receptor 2
(HER2)–positive primary breast tumors had metastatic tumors that were HER2 positive …

Background The discordance in oestrogen receptor (ER), progesterone receptor (PgR) and
human epidermal growth factor receptor 2 (HER2) status between primary and recurrent …

The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or
amplified in∼ 15% of breast cancer patients and was identified a quarter century ago as a …